Gilead Sciences (NASDAQ:GILD) CEO Sells $15,611,400.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer owned 566,698 shares of the company’s stock, valued at $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $124.83, for a total transaction of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.54, for a total transaction of $1,265,400.00.
• On Tuesday, October 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $139.72 on Thursday. The business’s fifty day moving average price is $124.76 and its two-hundred day moving average price is $119.24. The firm has a market capitalization of $173.35 billion, a PE ratio of 21.66, a P/E/G ratio of 0.74 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $141.71.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the firm posted $2.02 EPS. Gilead Sciences’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Phase‑3 Trodelvy combo beat Keytruda + chemo in a pivotal study, sparking a sharp rally and renewed bullish debate about Gilead’s oncology upside. Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial
• Positive Sentiment: Multiple analyst upgrades/price‑target raises (Citigroup to $156, Truist, BMO, UBS commentary) are reinforcing buy-side momentum and likely supporting higher valuations in the near term. Citigroup adjusts price target on Gilead Sciences to 156 from 140; maintains buy rating
• Neutral Sentiment: Gilead will report Q4 & full‑year 2025 results on Feb 10 — a clear near‑term catalyst that could amplify either the positive trial reaction or reveal operational headwinds. Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
• Neutral Sentiment: News aggregator and investor‑attention pieces (Zacks, sector writeups) are boosting visibility but are not new fundamental information. Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Short‑interest data in the feed shows zero shares/NaN (likely a reporting artifact) — not a reliable signal for positioning or squeeze risk today.
• Negative Sentiment: CEO Daniel O’Day sold 115,640 shares (~$15.6M) in late January, reducing his holding ~17% — a notable insider sale that market participants may view as a short‑term negative or liquidity event. SEC filing: Form 4 — Daniel Patrick O’day sale

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent analyst reports. Citigroup raised their price objective on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research note on Tuesday. Rothschild & Co Redburn upped their target price on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. TD Cowen increased their price objective on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Finally, Scotiabank began coverage on shares of Gilead Sciences in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $135.36.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently modified their holdings of the stock. GoalVest Advisory LLC grew its holdings in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences during the 3rd quarter worth $26,000. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences during the second quarter valued at $27,000. Financial Consulate Inc. lifted its position in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the period. Finally, Putney Financial Group LLC lifted its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.